Search
Now showing items 1-4 of 4
Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.
(Current Medicinal Chemistry, 2019)
DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells
(European Journal of Pharmaceutical Sciences, 2017)
Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.
(European Journal of Pharmaceutical Sciences, 2019)
A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors
(Lausanne : Frontiers Media, 2022)